Dr Reddy's Gets DCGI Approval For Esophageal Cancer Drug Zytorvi
· Business · Business Standard
Dr Reddy's Laboratories has secured Drugs Controller General of India approval for Zytorvi, a novel therapy for esophageal cancer. The domestically developed drug offers a new treatment option for a disease with limited existing therapies. The approval marks a significant milestone for India's biotech sector in addressing gastrointestinal cancers. Clinical data supporting the application has been pivotal in the regulatory clearance.
Why it matters
The approval provides Indian patients with a new domestically developed option for esophageal cancer, potentially reducing dependence on imported therapies. It validates India's capabilities in oncology drug development and could expand treatment accessibility.
Read the original report — Business Standard
Join us on Telegram
Breaking news the moment it lands. At 10,000 members we ship the Android app.